🔗 Share this article

A daily slimming tablet could assist people cut their weight by up to 20%, as per a study that might pave the way for countless people more people to shed pounds.

How the Drug Functions

This medication, called the oral treatment, focuses on the identical GLP-1 pathways as weight loss injections such as tirzepatide and semaglutide. In a trial of over 3,000 participants, 20% of users who took the once-a-day pill for 72 weeks lost at least one-fifth of their total weight.

Weight loss jabs are transformative, but oral forms represent a holy grail because they are easier to store, distribute and administer, and may also be projected to be cheaper, providing new optimism for many people attempting to reduce weight.

Orforglipron is a GLP-1 agonist, a class of medication that aids in reducing blood sugar readings, delays the digestion of food and may curb appetite.

Study Results and Convenience

Slimming results seen in people using the tablet is not as stark as those among patients using injectable alternatives, but specialists believe the tablet is more accessible and convenient than injections.

The drug is not yet authorized by the FDA or regulators in other countries. The manufacturer has said it expects significant interest when the new pill is released.

During the trial, the 3,127 patients were divided into cohorts receiving orforglipron tablets of varying strengths, while some took a dummy pill, for 72 weeks.

All of the patients were diagnosed with excess weight, indicating they had a body mass index reading of 30 or over, but they did not have diabetes. Patients from several nations took part in the study.

Key Results

Scientists found that following the study period users taking the smallest amount lost an average of 7.5% of their body weight. Participants taking the highest dose lost an average of 11.2% of their body weight.

Among patients taking the highest doses, more than half had a decrease of 10% or more of weight, over a third had a reduction of 15% or greater, and almost one-fifth had a reduction of 20% or more.

Researchers said additional wellness indicators also improved among participants taking the drug, such as better BP, a reduced waist size and a reduction in LDL levels.

The most common adverse reactions were gastrointestinal, which were described as manageable.

“In adults diagnosed with excess weight, long-term treatment using orforglipron resulted in significantly greater decreases in weight than inactive treatment,” researchers noted.

Future Benefits

Health experts have hailed weight loss treatments as game-changing. But shots involve additional logistical efforts for health services, so oral options could benefit many additional individuals trying to lose weight.

Additional research shows slimming jabs could be effective on children starting from six who have obesity or are diagnosed with diabetes. But, digestive issues were “significantly more common” in young users using the medications.

Experts emphasized that extended follow-up durations in future trials and additional practical analysis were crucial to establish the lasting effects.”